Peter B. Berger, MD
Co-Chair
|
 |
Glenn N. Levine, MD
Co-Chair
|
 |
You need to upgrade your Flash Player
|
|
You need to upgrade your Flash Player to view this content.
WHAT'S NEW
Dynamic Slide Library
We introduce our Dynamic Slide Library with in-depth information on clinical trials, antiplatelet drugs, stents, antithrombotic agents, and acute coronary syndromes.
|
Identifying and Addressing Unmet Needs in Platelet Inhibition in Cardiology
This CME-certified webcast features 3 cardiologists on the Expert Panel of plateletNEWS.org presenting various aspects of antiplatelet therapy. The contemporary use of antiplatelet therapy in acute coronary syndrome patients and those who undergo percutaneous coronary interventions is discussed. There is also robust discussion about unmet clinical needs in the field and novel antiplatelet therapy and the agents that are on the horizon.
|
Welcome to My Practice
Step inside the practices of the plateletNEWS.org faculty members and see how they manage complex cases, research, and teaching. Now available: Christopher P. Cannon, MD, Frederic Scott Resnic, MD, Glenn N. Levine, MD, and Steven D. Wiviott, MD.
|
|
IN THE NEWS
Tracing Metal Pollution Back To Its Sources
Nov 21, 2008 -- A new way of pinpointing where zinc pollution in the atmosphere comes from could improve pollution monitoring and regulation, says research out this week in the journal Analytical Chemistry. Imperial College London researchers say their work is a major breakthrough as current methods for analysing zinc pollution only measure pollution in the atmosphere; they do not trace it back to its source.
|
Aldagen Announces Positive Phase 1/2 Results For Critical Limb Ischemia Stem Cell Therapy ALD-301
Nov 21, 2008 -- Aldagen today announced positive results from its multicenter Phase 1/2 clinical trial of ALD-301, a novel stem cell therapy being developed for the treatment of critical limb ischemia. In the 24-week Phase 1/2 trial, ALD-301 was well tolerated.
|
Duska Therapeutics Applies For Phase 3 Special Protocol Assessment
Nov 21, 2008 -- Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA), announced that it has submitted its pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment (SPA) procedure with the U.S. Food and Drug Administration (FDA). Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase 3 clinical trial with its lead product ATPace.
|
Trellis(R) Peripheral Infusion System Removes Blood Clots In Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
Nov 21, 2008 -- Clinical data from a prospective registry presented this week at the 35th Annual Veith Symposium shows DVT treatment with the Trellis(R) Peripheral Infusion System from Bacchus Vascular, Inc. (Santa Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes. This technique, called isolated pharmacomechanical thrombolysis, restores blood flow more quickly and safely than current catheter-directed thrombolysis (CDT) techniques.
|
Portuguese Scientists Discover New Mechanism That Regulates Formation Of Blood Vessels
Nov 21, 2008 -- Researchers in one of the external groups of the Instituto Gulbenkian de Ciência (IGC), in Portugal, have discovered a novel mechanism which regulates the process whereby new blood vessels are formed and wounds heal, including chronic wounds, such as those found in diabetic patients and those suffering from morbid obesity.
|
|
Please enter both email and password to log in
|
|